If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Andrew Evens is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles
Hodgkin Disease Medicine & Life Sciences
Lymphoma, Large B-Cell, Diffuse Medicine & Life Sciences
Non-Hodgkin's Lymphoma Medicine & Life Sciences
Lymphoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
T-Cell Lymphoma Medicine & Life Sciences
Survival Medicine & Life Sciences
Hematopoietic Stem Cell Transplantation Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1998 2019

Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma

Passero, F. C., Ravi, D., McDonald, J. T., Beheshti, A., David, K. & Evens, A., Jan 1 2019, (Accepted/In press) In : British Journal of Haematology.

Research output: Contribution to journalArticle

T-Cell Lymphoma
Hodgkin Disease
Apoptosis
Therapeutics
Jurkat Cells

Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin

Badar, T., Hamadani, M., Bachanova, V., Maddocks, K. J., Umyarova, E., Chavez, J. C., Epperla, N., Chhabra, S., Xavier, A. C., Karmali, R., Salhab, M., Reddy, N., Glenn, M. J., Hernandez-Ilizaliturri, F. J., Flowers, C. R., Evens, A., Zhou, Z., Lansigan, F., Barta, S. K., Cohen, J. B. & 2 others, Fenske, T. S. & Costa, L. J., Mar 21 2019, In : Leukemia and Lymphoma. 60, 4, p. 940-946 7 p.

Research output: Contribution to journalArticle

Lymphoma, Large B-Cell, Diffuse
Treatment Failure
Drug Therapy
B-Lymphocytes
Ifosfamide

Important new developments in Hodgkin Lymphoma

Evens, A., Jan 1 2019, In : British Journal of Haematology. 184, 1, 1 p.

Research output: Contribution to journalEditorial

Hodgkin Disease
2 Citations (Scopus)

Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma

Hill, B. T., Nastoupil, L., Winter, A. M., Becnel, M. R., Cerhan, J. R., Habermann, T. M., Link, B. K., Maurer, M. J., Fakhri, B., Reddy, P., Smith, S. D., Mukhija, D., Jagadeesh, D., Desai, A., Alderuccio, J. P., Lossos, I. S., Mehra, P., Portell, C. A., Goldman, M. L., Calzada, O. & 9 others, Cohen, J. B., Hussain, M. J., Ghosh, N., Caimi, P., Tiutan, T., Martin, P., Kodali, A., Evens, A. & Kahl, B. S., Feb 1 2019, In : British Journal of Haematology. 184, 4, p. 524-535 12 p.

Research output: Contribution to journalArticle

Follicular Lymphoma
Maintenance
Observation
Therapeutics
Vincristine
2 Citations (Scopus)

Microfluidic assembly of hydrogel-based immunogenic tumor spheroids for evaluation of anticancer therapies and biomarker release

Sabhachandani, P., Sarkar, S., Mckenney, S., Ravi, D., Evens, A. & Konry, T., Feb 10 2019, In : Journal of Controlled Release. 295, p. 21-30 10 p.

Research output: Contribution to journalArticle

Microfluidics
Lymphoma, Large B-Cell, Diffuse
Hydrogel
Biomarkers
Tumor Microenvironment